News · 26 weeks18-67%
2025-10-262026-04-19
Mix790d
- SEC Filings6(86%)
- Other1(14%)
Latest news
25 items- SECArcadia Biosciences Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form 10-K filed by Arcadia Biosciences Inc.10-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- PRArcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights-- Zola® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed business combination -- -- Exercise of preferred investment options yields $2.1 million gross proceeds -- DALLAS, March 26, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the fourth quarter and full year of 2025. "At the end of 2025, we received a termination notice from Roosevelt Resources related to the Securities Exchange Agreement concerning a proposed business combination, signed in December 2024." said T.J. Schaefer, CEO of Arcadia. Schaefer continu
- SECSEC Form EFFECT filed by Arcadia Biosciences Inc.EFFECT - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form S-3 filed by Arcadia Biosciences Inc.S-3 - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form RW filed by Arcadia Biosciences Inc.RW - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- PRArcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross ProceedsDALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today announced that it has entered into definitive agreements for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 808,595 shares originally issued in December 2020, January 2021, August 2022 and March 2023, having an exercise price of $9.00 per share, at a reduced exercise price of $2.575 per share. The shares of common stock issuable upon exercise of the preferred investment options are registered pursuant to effective registration statements on Form S-1 (Registration Nos. 333-262407 and
- SECSEC Form 425 filed by Arcadia Biosciences Inc.425 - Arcadia Biosciences, Inc. (0001469443) (Subject)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- PRArcadia Biosciences (RKDA) Receives Termination Notice of the Proposed Business Combination with Roosevelt ResourcesDALLAS, Dec. 26, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today announced that on December 24, 2025, it received a notice from Roosevelt Resources, LP, terminating the Securities Exchange Agreement between Arcadia and Roosevelt dated December 4, 2024, pursuant to the terms of the agreement. The agreement provided for a proposed business combination transaction between the two companies. "In light of these circumstances, Arcadia will resume the process of evaluating strategic alternatives in order to create value for our shareholders." said T.J. Schaefer, CEO of Arcadia. Schaefer continued, "Over the last t
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form DEF 14A filed by Arcadia Biosciences Inc.DEF 14A - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form 10-Q filed by Arcadia Biosciences Inc.10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- PRArcadia Biosciences (RKDA) Announces Third Quarter 2025 Financial Results and Business Highlights-- Zola® year-to-date revenues increase 26% year over year ---- Arcadia gross profit margins exceed 30% for 11th straight quarter ---- Arcadia cash balance declines by only $257K to $1.1M -- DALLAS, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the third quarter of 2025. "We are very pleased with our performance for the third quarter of 2025." said T.J. Schaefer, CEO of Arcadia. "Zola® coconut water revenues were flat year-over-year in the third quarter as we overlapped the initial sell-in to Zola's largest customer during the third quarter of 2024
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form 10-Q filed by Arcadia Biosciences Inc.10-Q - Arcadia Biosciences, Inc. (0001469443) (Filer)
- SECSEC Form 425 filed by Arcadia Biosciences Inc.425 - Arcadia Biosciences, Inc. (0001469443) (Subject)
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)
- PRArcadia Biosciences (RKDA) Announces Second Quarter and First Half 2025 Financial Results and Business Highlights-- Arcadia revenues increase 11% year over year driven by 24% growth in Zola® -- -- Arcadia receives 2.7 million shares of stock in ABVE -- -- Arcadia eliminates $1M in liabilities -- DALLAS, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (NASDAQ:RKDA), a producer and marketer of innovative wellness products, today released its financial and business results for the second quarter and first half of 2025. "We are very pleased with our performance for the second quarter of 2025," said T.J. Schaefer, CEO of Arcadia. "While our total revenues have increased 11% compared to the second quarter of 2024, Zola® coconut water revenues have grown 24% and once aga
- SECArcadia Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Arcadia Biosciences, Inc. (0001469443) (Filer)